Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Estrella Immunopharma ( (ESLA) ) just unveiled an update.
Estrella Immunopharma, Inc. has appointed Dr. Cheng Liu as Director, President, and CEO with an ‘at will’ employment agreement offering a $250,000 annual salary, bonus potential, and equity incentives. The contract allows flexibility for termination and offers severance packages based on the circumstances, highlighting the company’s strategic focus on aligning leadership performance with financial and operational goals.
Find detailed analytics on ESLA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue